United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S grew its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 21.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 85,242 shares of the biotechnology company's stock after purchasing an additional 14,964 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned approximately 0.19% of United Therapeutics worth $30,077,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Newbridge Financial Services Group Inc. acquired a new stake in shares of United Therapeutics during the fourth quarter valued at about $25,000. Millstone Evans Group LLC acquired a new stake in United Therapeutics in the 4th quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB raised its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 58 shares during the period. Anchor Investment Management LLC lifted its stake in United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 30 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its position in shares of United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after buying an additional 258 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $956,195.85. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 91,500 shares of company stock valued at $30,971,540. Company insiders own 11.90% of the company's stock.

United Therapeutics Trading Down 0.2 %

UTHR stock opened at $284.73 on Friday. The company's 50 day moving average is $316.61 and its two-hundred day moving average is $348.66. United Therapeutics Co. has a twelve month low of $233.28 and a twelve month high of $417.82. The stock has a market cap of $12.79 billion, a P/E ratio of 12.50, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period in the previous year, the business posted $4.36 earnings per share. On average, equities research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on UTHR. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. HC Wainwright restated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.